In 2024, pharmaceutical companies collectively spent nearly $288 billion dollars on research and development. Scientists screened compounds, analyzed biomarkers, ran clinical trials, studied patient outcomes, and searched for the next breakthrough therapy.

At the same time, another resource was quietly growing inside these organizations.

Data.

Not just more data, but different kinds of data. Research findings. Clinical trial results. Genomic information. Real-world evidence. Manufacturing records. Patient outcomes. Commercial insights. Regulatory submissions. Scientific literature.

For years, much of this information remained confined to the function that generated it. Researchers focused on research data. Clinical teams focused on trial data. Manufacturing teams focused on operational metrics. Commercial organizations focused on market performance.

The challenge is that diseases do not exist in organizational silos.

Neither do the answers required to treat them.

As life sciences organizations face rising development costs, growing scientific complexity, and increasing pressure to improve patient outcomes, a fundamental shift is beginning to take place. The conversation is expanding beyond scientific discovery alone and toward a broader question: how effectively can organizations learn from the information they already possess?

The companies making the greatest progress are not necessarily generating more data than their peers. They are becoming better at connecting it.

Drug discovery has become an information challenge

The economics of pharmaceutical development have become increasingly difficult to ignore.

Research from the Tufts Center for the Study of Drug Development estimates that bringing a new drug to market can exceed $2.6 billion when accounting for failed candidates and capital costs. Development timelines frequently extend beyond ten years, while only a small percentage of compounds entering clinical development ultimately receive approval.

For decades, the industry's response was straightforward. Invest more heavily in research.

Today, that equation is becoming more complicated.

Scientific questions are becoming more complex. Many of the industry's most promising opportunities involve rare diseases, targeted therapies, cell and gene therapies, and highly personalized treatment approaches. These areas require organizations to evaluate larger volumes of information, understand increasingly complex biological interactions, and identify smaller patient populations with greater precision.

The challenge is no longer simply generating knowledge.

It is finding meaningful signals within an overwhelming amount of information.

More data does not automatically create more insight

Life sciences organizations are generating data at a scale that would have been unimaginable twenty years ago.

A single Phase II clinical trial involving 100 patients monitored over six months through wearable devices can generate more than 200 billion data points, according to research conducted by Intel and Kaiser Associates. At the same time, genomic sequencing technologies can produce terabytes of data from a single study, while decentralized trials increasingly incorporate information from electronic health records, remote monitoring devices, patient-reported outcomes, and real-world evidence sources. Clinical development teams now have access to a far richer picture of patient health and treatment effectiveness than ever before, but that information is often distributed across dozens of systems and stakeholders.

Yet despite this abundance of information, many organizations struggle to answer relatively simple questions:

• What can we learn from previous studies that may improve future trial design?
• Which patient populations are most likely to respond to a specific therapy?
• Are there early indicators that a trial is likely to encounter recruitment challenges?
• What patterns exist across manufacturing, clinical, and patient outcome data?

The issue is rarely the absence of data.

The issue is that the information often exists in separate systems, managed by different teams, governed by different processes, and structured in different ways.

As a result, valuable insights frequently remain hidden in plain sight.

Why the industry is investing heavily in data platforms

For years, technology investments in life sciences focused on digitization. Organizations implemented new systems, automated workflows, and expanded access to information.

Today, the focus is shifting toward connectivity.

Leading organizations are investing in enterprise data platforms that allow information from research, clinical development, manufacturing, regulatory, and commercial functions to be accessed through a more unified environment.

The objective is not simply to centralize data.

The objective is to create context.

A research scientist evaluating a promising target may benefit from insights generated during previous clinical studies. A clinical operations team designing a trial may benefit from historical recruitment data and real-world patient information. Manufacturing teams may identify quality trends that influence future development decisions.

When information moves more freely across the organization, the number of potential connections increases significantly.

Many of the most valuable discoveries occur not because new information is created, but because existing information is viewed through a broader lens.

AI is amplifying a trend that was already underway

Much of the public discussion surrounding AI focuses on its ability to generate content, automate tasks, or accelerate analysis.

Within life sciences, its most meaningful impact may be different.

AI is proving valuable because it can help researchers identify relationships across enormous volumes of information that would be difficult for humans to analyze independently.

Researchers are using advanced analytical techniques to identify novel drug targets, evaluate molecular structures, predict protein interactions, and prioritize compounds for further investigation. McKinsey estimates that AI could generate between $60 billion and $110 billion annually across pharmaceutical and medical-product industries, with a significant portion concentrated in research and development.

Yet these results are revealing an important lesson.

Organizations are discovering that AI performance is closely tied to data quality, accessibility, and context. Sophisticated algorithms cannot compensate for fragmented information, inconsistent definitions, or incomplete datasets.

In many cases, the limiting factor is not the technology itself. It is the environment in which the technology operates.

The organizations moving fastest are learning faster

One of the more significant shifts occurring across the industry is the growing recognition that learning speed may be becoming just as important as research scale. Historically, larger organizations benefited from greater resources, larger research teams, and broader development pipelines. While those advantages remain important, the ability to connect insights across research, clinical development, manufacturing, and commercial operations is increasingly shaping how quickly organizations can move from discovery to decision.

Organizations that identify promising signals earlier can allocate resources more effectively, while those that recognize weak signals sooner can redirect investments before costs escalate. Access to broader, more connected evidence sets also enables teams to make decisions with greater confidence throughout the development process.

Drug development will always involve uncertainty, and no amount of data can eliminate scientific risk. What data can improve is the quality, context, and completeness of the information used to navigate those decisions.

Building an environment where information can flow

As organizations look ahead, data strategy is becoming inseparable from research strategy. The conversation is no longer centered on storage, integration, or reporting alone. Leaders are increasingly focused on how information moves across the enterprise, who can access it, whether it can be trusted, and how quickly it can be translated into decisions.

These questions directly influence research productivity, clinical development timelines, and the ability to bring therapies to patients.

This is why many life sciences organizations are embracing continuous modernization. Rather than treating data initiatives as standalone projects, they are building connected environments that can evolve alongside scientific advances, regulatory requirements, and business priorities. The goal is not to create a perfect data ecosystem, but to reduce the friction between insight and action.

The future of discovery depends on connection

Scientific discovery will always remain at the heart of the pharmaceutical industry. Laboratories, researchers, and breakthrough science will continue to shape the future of medicine.

What is changing is the amount of information available to support that work.

As data volumes continue to grow across research, clinical development, manufacturing, and patient care, the organizations that can connect those sources most effectively are likely to spend less time searching for answers and more time acting on them.

The next blockbuster drug will still be discovered by scientists. But the path to that discovery may increasingly depend on an organization's ability to learn from the information it already has. Connect with our team to learn how modern data platforms, governance, and enterprise intelligence can help transform information into action.